Cel-sci Corp (CVM)

$1.5

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Cel-sci Corp

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.8% return, outperforming this stock by 95.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 237.7% return, outperforming this stock by 328.8%

Performance

  • $1.50
    $1.61
    $1.50
    downward going graph

    0.0%

    Downside

    Day's Volatility :6.83%

    Upside

    6.83%

    downward going graph
  • $1.04
    $3.23
    $1.50
    downward going graph

    30.67%

    Downside

    52 Weeks Volatility :67.8%

    Upside

    53.56%

    downward going graph

Returns

PeriodCel-sci CorpSector (Health Care)Index (Russel 2000)
3 Months
-38.27%
-0.7%
0.0%
6 Months
32.74%
7.7%
0.0%
1 Year
-47.0%
3.3%
-1.7%
3 Years
-91.06%
13.9%
-20.7%

Highlights

Market Capitalization
81.0M
Book Value
$0.25
Earnings Per Share (EPS)
-0.69
PEG Ratio
0.0
Wall Street Target Price
8.47
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-51.71%
Return On Equity TTM
-158.25%
Revenue TTM
28.6K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-62.7%
Gross Profit TTM
-25.4M
EBITDA
-28.1M
Diluted Eps TTM
-0.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.72
EPS Estimate Next Year
-0.49
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Cel-sci Corp(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 464.67%

Current $1.50
Target $8.47

Technicals Summary

Sell

Neutral

Buy

Cel-sci Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cel-sci Corp
Cel-sci Corp
-26.11%
32.74%
-47.0%
-91.06%
-75.61%
Moderna, Inc.
Moderna, Inc.
-2.96%
23.83%
-28.58%
-37.0%
331.65%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.23%
10.55%
10.52%
78.91%
167.64%
Novo Nordisk A/s
Novo Nordisk A/s
-6.56%
25.69%
48.76%
237.69%
410.4%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
7.86%
19.8%
79.52%
133.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cel-sci Corp
Cel-sci Corp
NA
NA
0.0
-0.72
-1.58
-0.52
NA
0.25
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.8
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.3
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cel-sci Corp
Cel-sci Corp
Buy
$81.0M
-75.61%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.1B
331.65%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
167.64%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
410.4%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.49%
28.42
36.68%

Corporate Announcements

  • Cel-sci Corp Earnings

    Cel-sci Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.

Organization
Cel-sci Corp
Employees
0
CEO
Mr. Geert R. Kersten Esq.
Industry
Health Technology

FAQs